Does empagliflozin provide consistent efficacy and safety in heart failure patients regardless of previous coronary revascularization history?
Empagliflozin demonstrates consistent efficacy and safety in heart failure patients irrespective of prior coronary revascularization.
In this large HF trial program, revascularized patients with HF exhibited similar rates of HF and ischemic events as those without prior revascularization. The efficacy and safety of empagliflozin in HF were consistent in those with and without a revascularization history.
Dhingra et al. (Thu,) studied this question.